Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RMC-LUNG-101D: Zoldonrasib in Previously Treated RAS G12D-Mutant NSCLC
2025-521681-10-00Phase 2Authorised
- Sponsor
- Revolution Medicines
- Start
- Sep 2025
- Modality
- Small Molecules
- Countries
- 16
01
Overview
Phase 2, open-label, single-arm trial of zoldonrasib in non-small cell lung cancer (NSCLC), sponsored by Revolution Medicines. Primary endpoint: Confirmed objective response rate (ORR) per RECIST v1.1 by BICR. Planned start Sep 2025; status: authorised.
02
Drugs
zoldonrasib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2025-521681-10-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-521681-10-00.